摘要
目的:分析恩美曲妥珠单抗(trastuzumab emtansine, T-DM1)所致不良反应(adverse drug reactions, ADR)的特点,为临床用药提供参考。方法:检索PubMed、Embase、SCI、CNKI、万方、VIP数据库收载的T-DM1致ADR的个案报道并进行分析。结果:纳入T-DM1致ADR个案报道29篇共36例,均为女性,年龄40~69岁的居多(28例,占比77.78%),原患疾病除1例为肺腺癌外,均为乳腺癌。发生时间范围为1 d~30个月,主要集中在用药12个月内,累及全身皮肤、肝胆、呼吸、眼等8个系统-器官。36例患者中,31例经停药或减量和(或)对症治疗后,27例好转,4例死亡。其中,2例伴色素沉着,1例发生肝转移。结论:临床医师和药师应关注T-DM1致ADR,做好用药监护及用药后随访,保证临床用药安全。
OBJECTIVE To analyze the characteristics of adverse drug reactions(ADRs)caused by trastuzumab emtansine(T-DM1)and provide reference for clinical medication.METHODS The case reports of ADRs caused by T-DM1 recorded in PubMed,Embase,SCI,CNKI,Wanfang and VIP databases were retrieved and analyzed.RESULTS There were 29 reports on ADR cases caused by T-DM1,including 36 cases in total,and all of them were female,most of them were aged from 40 to 69 years old(28 cases,accounting for 77.78%).The original disease was breast cancer except one case of lung adenocarcinoma.The occurrence time range was from 1 day to 30 months,mainly concentrating within 12 months of medication,and involving 8 systems and organs such as skin,liver and gallbladder,respiration and eyes,etc.Totally 31 patients of the 36 cases were with drug withdrawal or reduction and/or symptomatic treatment,and 27 patients were improved while 4 patients died.Among them,2 patients were with pigmentation,and one developed liver metastasis.CONCLUSION Clinicians and pharmacists should pay attention to ADRs caused by T-DM1,and do a good job of medication monitoring and follow-up after medication to ensure the safety of clinical medication.
作者
邵鑫
蒋先虹
黎风
郭冬杰
SHAO Xin;JIANG Xianhong;LI Feng;GUO Dongjie(Pharmacy Department of Leshan People's Hospital,Sichuan Leshan 614000,China;Gastrointestinal Surgery Department of Leshan People's Hospital,Sichuan Leshan 614000,China;Department of Pharmacy,Affiliated Hospital of North Sichuan Medical College,Sichuan Nanchong 637000,China;Pharmacy Department of China Japan Friendship Hospital,Beijing 100029,China)
出处
《中国医院药学杂志》
CAS
北大核心
2023年第17期1975-1979,共5页
Chinese Journal of Hospital Pharmacy
基金
中国药学会全国医药经济信息网2020年重点项目[编号:CMEI2020KPYJ(ZAMM)00305]。
关键词
恩美曲妥珠单抗
不良反应
文献分析
trastuzumab emtansine
adverse reactions
document analysis
